BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Jeffrey S. Williams Joins Alexza Molecular Delivery Corporation (MDC) As Senior Vice President


10/19/2005 5:10:38 PM

PALO ALTO, Calif., March 30 /PRNewswire/ -- Alexza Molecular Delivery Corporation ("Alexza") announced today that Jeffrey S. Williams has joined the company as Senior Vice President, Corporate and Business Development. Mr. Williams, a 15-year industry veteran, will have primary responsibility for corporate and business development, facility operations and information technology. From 2001 to 2004, Mr. Williams was Vice President, Corporate Development and a member of the founding management team at Scion Pharmaceuticals, Inc. He was Vice President, Office of Development at Anesta Corp. until 2001, when Anesta was acquired by Cephalon, Inc. He started his career with positions at Phase V Technologies, Inc. and Vertex Pharmaceuticals, Inc.

"I am very pleased to welcome Jeff to our Alexza management team," said Thomas B. King, President and CEO. "The combination of Jeff's passion for success and his leadership expertise represents an ideal phenotype to lead our business and corporate development efforts."

"I am thrilled to be joining Alexza, with its creative and committed team of scientists, engineers and staff," said Williams. "Alexza's novel technologies will provide substantial business and corporate development opportunities."

Dr. Alejandro Zaffaroni, renowned biotechnology pioneer and investor, founded Alexza. Alexza is a specialty pharmaceutical company developing products using the company's core platform, Staccato(TM) technology. The Staccato(TM) technology enables the rapid onset of therapeutic effect of many small molecule drugs as well as patient titration to the lowest effective dose to better treat acute and intermittent conditions. In addition to developing its own pipeline, focusing initially on central nervous system indications representing more than $15 billion in annual US sales, the company plans to also strategically partner its technology with pharmaceutical companies.

Alexza Molecular Delivery Corporation

CONTACT: Thomas B. King, President & CEO of Alexza Molecular DeliveryCorporation, +1-650-687-3902



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES